Last reviewed · How we verify
NCT05498935
Prolonged Cardiopulmonary Bypass Time as a Predictive Factor for AGI After Heart Valve Replacement
trial testing CPB time in Heart Valve Diseases in 1,070 participants. Completed in 2 January 2024.
2 January 2024
Quick facts
| Lead sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,070 |
| Start date | 10 August 2022 |
| Primary completion | 2 January 2024 |
| Estimated completion | 2 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CPB time
Conditions studied
- Heart Valve Diseases — all drugs for Heart Valve Diseases →
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Who can join
Adults 18 to 70, any sex, with Heart Valve Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this retrospective study, the investigators will analyze the correlation between cardiopulmonary bypass (CPB) time and acute gastrointestinal injury (AGI), and the outcomes of AGI in patients undergoing heart valve replacement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05498935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Valve Diseases
Currently open trials in the same condition.
- NCT07390903 — GLS in Difficult CPB Weaning · recruiting
- NCT07099859 — Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Unde · Phase 4 · recruiting
- NCT06215378 — Antagonization of Heparin With Protamine Sulfate After TAVI · Phase 3 · recruiting
- NCT06445231 — Echocardiography in Nursing Home · NA · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials
Trials by the same sponsor.
- NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
- NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
- NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
- NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
- NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05498935 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
- Last refreshed: 3 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing